Clinical trials: RA - Rheumatoid Arthritis
- Condition RA - Rheumatoid Arthritis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Degenerative Hip Joint Disease, Rheumatoid Arthritis (RA)
Study to Evaluate the Safety and Efficacy of OR3O™ Dual Mobility System vs. Conventional Single Bearing Design Total Hip System
The purpose of this study is to compare OR3O™ Dual Mobility System to a conventional, single-bearing design Total Hip System in subjects who undergo Primary THA.
- Conditions
- Degenerative Hip Joint Disease, Rheumatoid Arthritis (RA), Femoral Neck Fractures, Avascular Necrosis of Femoral Head
- Trial name
- OR3O (NCT04941729)
- Testing
- OR3O™ - Dual Mobility System, Conventional
- Where
- 4 sites in China
- Volunteers
- 24 people
- Sponsor
- Smith & Nephew Medical (Shanghai) Ltd
Rheumatoid Arthritis (RA)
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function.
- Trial name
- NCT04888585
- Testing
- ABBV-154
- Where
- 220 sites in United States, Australia and 19 more
- Volunteers
- 473 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the…
- Trial name
- NCT03086343
- Testing
- Abatacept, Upadacitinib
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 657 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
The study objectives of Period 1 of this study were to compare the efficacy, safety, and tolerability of upadacitinib versus placebo for the treatment of signs and symptoms of subjects from China and selected countries including…
- Trial name
- NCT02955212
- Testing
- Upadacitinib
- Where
- 43 sites in Brazil, China and 1 more
- Volunteers
- 338 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib
This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in participants with rheumatoid arthritis (RA) who…
- Trial name
- NCT03823378
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 30 sites in Belgium, Canada and 5 more
- Volunteers
- 97 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.
- Trial name
- NCT03823391
- Testing
- ABBV-3373, Adalimumab
- Where
- 30 sites in United States, Germany and 5 more
- Volunteers
- 48 people
- Sponsor
- AbbVie
Rheumatoid Arthritis RA
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a.
- Trial name
- NCT03410056
- Testing
- Efavaleukin alfa
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Rheumatoid Arthritis (RA)
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
This was a phase 2 study to evaluate the safety and efficacy of elsubrutinib (ELS) and ABBV-599 (ELS plus upadacitinib [UPA]) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)…
- Trial name
- NCT03682705
- Testing
- Elsubrutinib, Upadacitinib
- Where
- 115 sites in United States, Belgium and 7 more
- Volunteers
- 242 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)
The purpose of this study is to assess the safety and efficacy of MK-8457 + Methotrexate (MTX) in participants with active rheumatoid arthritis (RA) despite MTX therapy.
- Trial name
- NCT01569152
- Testing
- MK-8457 100 mg, Methotrexate
- Volunteers
- 82 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis (RA)
Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents
The rationale for this study is to further explore if development of antibodies against TNF-α blocking agents is associated with reduced clinical effect/worsened clinical outcome.
- Trial name
- NCT01691014
- Testing
- non-interventional study
- Where
- 13 sites in Denmark
- Volunteers
- 79 people
- Sponsor
- Pfizer
Rheumatoid Arthritis (RA)
Methotrexate-Inadequate Response Study
The purpose of this study is to determine whether a weekly subcutaneous dose of abatacept yields clinical efficacy comparable to that of monthly intravenous doses of abatacept in participants with rheumatoid arthritis and an…
- Trial name
- NCT00559585
- Testing
- Subcutaneous (SC) Abatacept, Intravenous (IV) Abatacept
- Where
- 203 sites in United States, Argentina and 22 more
- Volunteers
- 2,492 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis (RA)
Phase IIIB Subcutaneous Abatacept Monotherapy Study
To evaluate safety and immunogenicity of abatacept when used with or without methotrexate in the absence of an IV loading dose of abatacept
- Trial name
- NCT00547521
- Testing
- abatacept, Methotrexate (MTX)
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 119 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis (RA)
Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
Relative Bioavailability Comparison study
- Trial name
- NCT01618968
- Testing
- MTX
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Antares Pharma Inc.
Rheumatoid Arthritis (RA)
Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device
The purpose of this study is to assess the usability of the VIBEX MTX device for SC self-injection of methotrexate.
- Trial name
- NCT01618955
- Testing
- VIBEX MTX
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Antares Pharma Inc.
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA
EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries
This is a non-interventional, post-marketing, observational study (PMOS) in which Humira (adalimumab) is prescribed in the usual manner in accordance with the terms of the local marketing authorization with regards to dose…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA, Rheumatoid Arthritis (RA
- Trial name
- EviraEAST (NCT01078402)
- Where
- 163 sites in Croatia, Hungary and 5 more
- Volunteers
- 809 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis (RA)
Methotrexate - Inadequate Response Device Sub-Study
The purpose of this study is to determine the safety and acceptability of a device used in place of traditional syringes for abatacept self-injection.
- Trial name
- MTX-IR (NCT01173120)
- Testing
- Abatacept combination product (ACP)
- Volunteers
- 62 people
- Sponsor
- Bristol-Myers Squibb